Drugs / Tranylcypromine
Tranylcypromine
also known as
NSC-757342 · NSC-80664 · Parnate · Parstelin · TCP · Tranilcipromina · TRANYLCYPROMINE SULFATE · Tranylcypromine sulphate
Small molecule targets MAOA via inhibition
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | PARNATE | — | 1984-03-22 | fda.gov ↗ |
| Approved | US (FDA) | PARNATE | — | 1961-02-21 | fda.gov ↗ |
Trials 12
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT02273102 | Mar 2015 → Nov 2018 | acute myeloid leukemia, myelodysplastic syndrome | University of Miami | Completed | No outcome recorded |
| Phase 1 | NCT00653393 | Oct → Nov 2004 | — | Par Pharmaceutical, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00223691 | Mar 2002 → Jan 2017 | autonomic nervous system disorder, orthostatic hypotension | Vanderbilt University | Completed | Mixed |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT02717884 | May 2015 → Dec 2020 | acute myeloid leukemia, myelodysplastic syndrome | Michael Luebbert | Unknown | No outcome recorded |
| Phase 1/2 | NCT02261779 | Sep 2014 → Sep 2017 | acute myeloid leukemia | Martin-Luther-University Halle-Wittenberg | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02374567 | Jan 2015 → Jun 2017 | anxiety disorder, dementia, depressive disorder, schizophrenia +1 | Hannover Medical School | Terminated | No outcome recorded |
| Phase 45 trials | ||||||
| Phase 4 | NCT01430455 | Nov 2011 → Feb 2014 | bipolar disorder | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 4 | NCT01031810 | Nov 2009 → Mar 2013 | major depressive disorder | New York State Psychiatric Institute | Terminated | No outcome recorded |
| Phase 4 | NCT00296686 | Sep 2001 → Aug 2006 | major depressive disorder | New York State Psychiatric Institute | Terminated | No outcome recorded Stop: Business |
| Phase 4 | NCT00177567 | Jul 2001 → Jan 2004 | bipolar disorder | University of Pittsburgh | Completed | No outcome recorded |
| Phase 4 | NCT00021528 | Jul 2001 → Sep 2006 | major depressive disorder | National Institute of Mental Health (NIMH) | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00012558 | Sep 1998 → Sep 2005 | bipolar disorder | National Institute of Mental Health (NIMH) | Completed | Mixed |
| Comparator or background therapy3 trials | ||||||
| Phase 1/2 | NCT00612807 Background | Jul 2006 → Jun 2010 | major depressive disorder | Duke University | Completed | No outcome recorded |
| — | NCT01944657 Comparator | Sep 2013 → Dec 2015 | major depressive disorder | Sheppard Pratt Health System | Withdrawn | No outcome recorded Stop: Enrollment |
| — | NCT01896349 Background | Apr 2013 → Aug 2014 | — | Hospital de Clinicas de Porto Alegre | Unknown | No outcome recorded |
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 16 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tranylcypromine | “Sequential Tranylcypromine (TC), TC + Dextroamphetamine and TC + Triiodothyronine for Refractory Depression” NCT00296686 ↗ |
| Known as | NSC-757342 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989843 ↗ |
| Known as | NSC-80664 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989843 ↗ |
| Known as | Parnate | “tranylcypromine (Parnate and others)” NCT01944657 ↗ |
| Known as | Parstelin | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989843 ↗ |
| Known as | TCP | “ATRA and tranylcypromine (TCP), an irreversible Monoamine-Oxidase (MAO) and Lysin-specific demethylase (LSD) inhibitor” NCT02261779 ↗ |
| Known as | Tranilcipromina | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989843 ↗ |
| Known as | TRANYLCYPROMINE SULFATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989843 ↗ |
| Known as | Tranylcypromine sulphate | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989843 ↗ |
| Action | Inhibit | “MAO-Inhibitor 60mg-120mg” NCT01031810 ↗ |
| Modality | Small molecule | — CHEMBL3989843 ↗ |
| Route | Oral | “Tranylcypromine started with 10mg/d up to a maximum dose of 60mg/d for on year, administered orally as tablets” NCT02261779 ↗ |
| Target | MAOA | “Most importantly, the MAO-A biomarker is known to be the single pharmacologic target of the treatment” NCT01031810 ↗ |